Navigation Links
Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million
Date:1/13/2011

Committee permitting the resumption of enrollment of Japanese patients in the Japan cohort of the study.  In consideration of these accelerated milestone payments from Yakult, the Company has agreed to reduce future drug approval milestone payments by approximately 40%. Among other separate prescribed events, receipt by the Company of the second $2.0 million from Yakult is a mandatory conversion event for the convertible preferred stock.

The transaction is expected to close on or about January 14, 2011, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the sale of the Units pursuant to this offering for general corporate purposes, including the funding of the clinical development of its product pipeline of cancer drugs.

Michael H. Tardugno, Celsion's President and Chief Executive Officer, commented, "Through an innovative, shareholder-minded approach to financing, Celsion has secured the capital that is expected to enable it to meet certain key clinical goals at terms that are supportive of all our shareholders.  We believe that we now have the financial runway sufficient to complete enrollment in our Phase III primary liver cancer trial, the HEAT study, as well as other related clinical and CMC milestones in 2011.

All of the shares of preferred stock and warrants to purchase shares of common stock are being offered pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"), which was declared effective by the SEC on April 17, 2009, as supplemented by a prospectus supplement dated January 12, 2011 filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended.

Dominick & Dominick LLC acted as placement agent for the offering.  The Units may only be offered by means of a prospectus. Copies of the prospectus supplement and accompanying base prospectus
'/>"/>

SOURCE Celsion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Celsion Announces Date and Time Change for Third Quarter 2010 Financial Results Conference Call to Monday, November 15, 2010
2. Celsion Reports Third Quarter 2010 Financial Results and Provides Business Update
3. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
4. Pharmos Corporation Reports 2008 Second Quarter Results
5. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
6. Genaera Corporation Announces Second Quarter Financial Results
7. MannKind Corporation Reports Second Quarter Financial Results
8. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
9. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
10. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)...  Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
(Date:7/10/2014)... Understanding the need for better quality and higher ... that currently exists in this area, ChanTest has recently ... validated ion channel and GPCR cell lines. ChanTest’s ... channels control many critical physiological functions throughout the body. ... to treat a variety of human diseases. , ...
(Date:7/10/2014)... QC (PRWEB) July 10, 2014 EvoDerma ... and convenience. This rejuvenating device now comes with a second ... develops over time. , The new cup is thinner on ... design works to target rough, thin and uneven surfaces on ... firm cup for a stimulating treatment on areas such as ...
(Date:7/10/2014)... 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, the ... announced an agreement with Lineagen, Inc., to ... NextStep Dx PLUS.  Lineagen, focused on ... disorders, currently offers FirstStep Dx PLUS, ... used by healthcare providers as a first-line ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... NWBS and NWBT; OTC Bulletin Board: NWBO) (the,"Company") announces ... Holdings,through the subscription of 1,000,000 new shares in the ... The new stock is expected to be admitted ... will not be tradable on the,Company,s OTC bulletin board ...
... (TSX-V: ICO) is pleased to announce the completion of ... company with sufficient capital to develop iCo-007 through to ... is targeting the treatment of Diabetic Macular Edema. The ... working capital. iCo,s partner Isis Pharmaceuticals Inc., (NASDAQ: ...
... Technologies (Celsis,IVT), a division of Celsis International plc, ... and Wisconsin-based Promega Corp,will take the trial and ... Celsis IVT is pre-qualifying lots of its extensive ... including,the P450-Glo(TM) CYP Assay used to study cytochrome ...
Cached Biology Technology:Northwest Biotherapeutics Secures $700,000 Equity Financing 2iCo Therapeutics Closes $1.3 Million Private Placement 2iCo Therapeutics Closes $1.3 Million Private Placement 3Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 2Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 3
(Date:7/11/2014)... 2014---A team of researchers from The Chinese University of ... gene of wild soybean linked to salt tolerance, with ... saline soil. This study published online in Nature ... genomic information for crop improvement. , Soybean is an ... human selection, cultivated soybeans have less genetic diversities than ...
(Date:7/11/2014)... Social animals often develop relationships with other group members ... In wild chacma baboons the strategy for grooming activities ... are just published in the scientific journal Biology ... of baboons is not practiced without ulterior motives. To ... for the individual, while grooming another individual can provide ...
(Date:7/11/2014)... from Ume University, Sweden, have explored two different ... reaction sequence leading to the formation of oxygen ... published in the scientific journal Nature Communications ... present day synthetic catalysts for water oxidation, which ... for the direct storage of solar energy in ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2
... of 70 scientists from the U.S., China, Australia and Japan ... "sacred lotus," which is believed to have a powerful genetic ... aging successfully. The scientists sequenced more than 86 percent of ... , which is revered in China and elsewhere as a ...
... 2013 In a groundbreaking move that provides new insight ... University have successfully sequenced the complete genome of a Scarlet ... by Drs. Christopher Seabury and Ian Tizard at the Schubot ... & Biomedical Sciences at Texas A&M. Their work is published ...
... in Nature , researchers at NYU School of ... tumor cells feed themselves, opening up new therapeutic possibilities ... Pancreatic cancer kills nearly 38,000 Americans annually, making it ... for most people diagnosed with it is less than ...
Cached Biology News:Scientists sequence genome of 'sacred lotus,' which likely holds anti-aging secrets 2Scientists sequence genome of 'sacred lotus,' which likely holds anti-aging secrets 3Scientists sequence genome of 'sacred lotus,' which likely holds anti-aging secrets 4Saving the parrots: Texas A&M team sequences genome of endangered macaw birds 2Breakthrough in how pancreatic cancer cells ingest nutrients points to new drug target 2
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Antibodies were affinity purified using epitopes specific to UBAP2L/NICE4 immobilized on solid support....
... plant total protein western blot ... screening tissue specific protein expression ... total protein is included in ... control for comparison between different ...
Biology Products: